Refractory acute lymphoblastic leukemia (ALL) is often incurable, and relapse rates following allogeneic bone marrow transplantation (BMT) remain high. 
T cell surveillance of residual leukemia is thought to be essential in achieving durable remission following allogeneic bone marrow transplantation (BMT). [1] [2] [3] [4] [5] [6] Although few studies have addressed the role of donor-derived ␥␦ + T cells in BMT, it is known that ␥␦ + T cells can mediate direct cytolytic activity to some human tumor cell lines. 7, 8 We previously reported a series of 10 leukemia patients who developed a persistent increase in donor-derived circulating CD3 +
CD4
Ϫ CD8 Ϫ V␦1 + ␥␦ + T cells between 60 and 270 days post BMT. Eight of these patients are surviving and remain free of disease (80%) at 5.5 years following BMT, as compared to 10/33 with a normal number of ␥␦ + T cells (P = 0.009). 9 We have also shown that enrichment of the marrow graft with ␥␦ + T cells favors an increase in these cells and therefore a decreased incidence of relapse. 10 Of interest, eight of eight patients in our series with a persistent increase in ␥␦ + T cells who were transplanted for acute lymphoblastic leukemia (ALL) are all alive and well at up to 6 years. The ability to deliver allogeneic cell therapy with known antileukemic efficacy without the risk of graft-versus-host disease (GVHD) would be very useful in the treatment of or prophylaxis against relapsed leukemia following BMT. It is generally thought that T lymphocytes recognize and eliminate residual leukemia through both MHC restricted and non-restricted pathways. 11 Targets for a graft-versusleukemia (GVL) effect may include minor and/or major mismatched histocompatibility antigens and/or leukemiaspecific antigens. 12, 13 It is known that patients who suffer from chronic GVHD post BMT often have a reduced rate of leukemic relapse, 1,2 possibly due to more intense alloreactivity against residual host-derived leukemic cells. Many investigators have shown evidence that GVHD and GVL effects can be separated to some degree, [3] [4] [5] 14, 15 although a system for engineering a GVL effect in the total absence of GVHD has not been reliably demonstrated. However, clinical and laboratory studies in humans suggest that ␥␦ + T cells may not be primary effectors of GVHD. These findings are consistent with data from our laboratory that show no correlation between increased ␥␦ + T cells and the development of GVHD. 9, 10 In this study, we investigated the response of donorderived ␥␦ + T cells in response to recipient primary acute leukemic blasts in culture and to normal mononuclear cells (MNC) in the allogeneic mixed lymphocyte reaction (MLR). The observations lend further support to our clinical data and suggest ␥␦ + T cells as an effective immunotherapeutic approach for acute lymphoblastic leukemia, a disease that has historically been resistant to cell-based therapy following relapse.
Materials and methods

Preparation of donor and recipient cells
Leukemic cells were obtained from patients presenting at relapse, isolated to give a cell population of Ͼ95% blasts, and cryopreserved until donor selection was complete. Donor blood was obtained and MNC enriched for ␥␦ + T cells by depletion of most ␣␤ + T cells using anti-CD4 and anti-CD8 coated immunomagnetic microspheres (Dynal, Lake Success, NY, USA) to give 10:1 and 5:1 bead to tar-get cell ratios, respectively. The degree of ␣␤ T cell depletion was determined by flow cytometry and was Ͻ5% of the initial number of ␣␤ + T cells.
Culture and activation of ␥␦ + T cells
All washes and cultures were performed in AIM-V medium (Life Technologies, Gaithersburg, MD, USA) supplemented with 25 IU/ml IL-2 (R&D Systems, Minneapolis, MN, USA) and 15% heat-inactivated fetal bovine serum (FBS) (patients 1-5) or 15% human AB serum (Sigma, St Louis, MO, USA) (patients 6-9). Donor MNC depleted of CD4 + /CD8 + T cells were plated on to 24-well plates (BD Biosciences, San Jose, CA, USA) at a density of 1 × 10 6 cells/well, an appropriate number of which were pre-coated with a pan-TCR ␥␦-specific monoclonal antibody (Endogen, Woburn, MA, USA). Cryopreserved recipient blast cells were thawed and resuspended to a density of 1 × 10 6 cells per ml, irradiated with a dose of 50 Gy and plated at 1 ml/well. Donor CD4/8-depleted cells were plated in the presence of an equal number of leukemic stimulator cells, but in the absence of immobilized antibody, and vice versa. At weekly intervals, cells from culture wells were immunophenotyped by flow cytometry, and viable cell counts performed in order to determine proliferative activity. After 2 weeks, the cell cultures were restimulated with freshly thawed blast cells. The functional assays described below were typically performed 4-6 weeks after culture initiation.
Flow cytometric immunophenotyping
The cultured cells were analyzed by four-color flow cytometry for expression of CD45, CD3, CD4, CD8, CD19, CD56, CD25, HLA-DR, CD69 (BD Biosciences), and V␦1 (Endogen), TCR-␥␦, CD57, CD94, and V␦1-V␦3 (Beckman Coulter, Miami, FL, USA). At least 50 000 ungated events were collected in a list mode file and expressed as a percentage of the total lymphocyte population.
Flow cytometric binding assay
Binding of donor ␥␦ + T cells to specific targets was examined by flow cytometry. Donor ␥␦ + T cells were incubated in AIM-V supplemented with 15% FBS (patients 1 and 3) or human AB serum (patient 7) for 30 min at 37°C, centrifuged, and resuspended in phosphate-buffered saline (PBS). The cell suspension was labeled with one mAb specific for an antigen expressed by the leukemia but not expressed by ␥␦ + T cells (CD19 or CD33 for ALL and AML, respectively) and anti-TCR ␥␦, which is not expressed by the leukemia. The cell preparation was incubated at 4°C for 30 min, washed three times, and analyzed by flow cytometry as detailed above. Dual-positive cells with increased forward and side scatter were scored as bound blast/␥␦ + T cell clusters. Positive and negative controls consisted of cultures of resting and activated donor ␥␦ + T cells against K562 cell targets. Resting ␥␦ + T cells do not bind K562 while activated ␥␦ + T cells do.
Cytotoxicity assay
Third-party mononuclear cells, the NK target cell K562, lymphoid lines MOLT-4 and Raji, EBV transformed B cells, myeloid lines KG1A and KBM5, third-party AML and recipient primary leukemia cells were used as targets. Aliquots of target cells were labeled overnight with 3,3Ј-dioctadecyloxacarbocyanine (DiOC 18 ) (Molecular Probes, Eugene, OR, USA). Cells were then washed in PBS and resuspended in RPMI-1640 with 10% FBS at a concentration of 2 × 10 4 cells/ml. Control MNC and ␥␦ + T cells were suspended in RPMI-1640 and diluted to yield effector to target (E:T) ratios of 40:1-2.5:1 and added to the target cells. Aliquots of propidium iodide (PI) in PBS (Molecular Probes) were then added to the cell mixtures. The cells were pelleted by centrifugation, incubated for 4 h, and then analyzed for green fluorescence (DIOC 18 Ϫ 560 nm) and red fluorescence (P Ϫ 630 nm). Analysis on a two-parameter scatter plot allows separation of live target cells (DiOC 18 ϩ PIϪ) and membrane-compromised targets are (DiOC 18 ϩ PIϩ) from which % cytotoxicity was calculated.
Mixed lymphocyte culture
MNC were prepared from an HLA-mismatched pair of normal donors and resuspended in AIM-V medium supplemented with 20% human AB serum. Cells from the stimulator were irradiated, resuspended to a concentration of 5.0 × 10 5 /ml, and dispensed in 100 l aliquots into two flat-bottom 96-well plates (BD Biosciences). Responder MNC were divided into two tubes and one was depleted of Ͼ98% ␣␤ + T cells using immunomagnetic microspheres coated with anti-CD4 and anti-CD8 mAbs. T cells pre-and post-T cell depletion (TCD) were enumerated using flow cytometry for CD3, CD4, CD8 and TCR-␥␦. The TCD fraction was then resuspended to give a T cell concentration equal to the fraction that was not depleted of T cells. TCD and non-TCD responder cells were then dispensed in triplicate in 100 l aliquots of 5 ϫ 10 5 cells/ml in both empty wells and wells containing stimulator cells. TCD cultures were supplemented with 25 U/ml IL-2, as it has been shown from previous experiments in our laboratory that ␥␦ + T cells require this concentration of IL-2 to sustain in vitro proliferation. Cultures were incubated at 37°C in a humidified atmosphere containing 5% CO 2 for 5 days. One plate was pulsed with 100 Ci/well (c, d) . The donor ␥␦ ϩ T cells bind avidly to recipient ALL (A) and exhibit strong cytotoxicity (b) against recipient ALL (᭹) and cytotoxicity to K562 cells (). Some toxicity against a third-party mononuclear cell preparation is seen at the higher E:T range (̄). In contrast, little if any binding is seen from donor ␥␦ ϩ T cells against recipient AML (c) and cytotoxicity against AML (᭹) is not different from cytotoxicity (d) against a third-party mononuclear cell preparation (̄). Cytotoxicity against K562 cells is present but diminished ().
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Results
Patient accrual and culture results are shown in Table 1 . Donor-derived ␥␦ + T cells proliferate both in response to immobilized pan-␦ mAb (200-to 1000-fold in 4 weeks) and to recipient-derived leukemic blasts cultured in combination with immobilized pan-␦ mAb (800-to 1200-fold in 4 weeks). The pan-␦ mAb was not required for activation and proliferation of V␦1 + CD4 Ϫ CD8 Ϫ ␥␦ + T cells against blasts, although the effect was shorter-lived than cultures in which immobilized antibody was used to support the growth of the ␥␦ + T cells. All ␥␦ + T cells from the cultures were CD3 + CD4 Ϫ CD8
Ϫ and expressed T cell activation-associated antigens CD69 and HLA-DR. Proliferating ␥␦ + T cells from cultures on pan-␦ mAb with primary ALL blasts preferentially expressed V␦1 (Table 1 ). In five cases (patients 1, 3, 7, 8 and 9) donor ␥␦ + T cells bound the blasts, but cell numbers from patient 7 were insufficient to perform a full cytotoxic assay. In the cultures where ␥␦ + T cells were in sufficient quantity to test (patients 1, 3 and 8), strong binding ( Figure 1a ) and cytotoxicity (Figure 1b) against the ALL was demonstrated. In all cases, the ALL blasts were MHC class I and class II positive. Donor ␥␦ + T cells from ALLbased cultures were cytotoxic to lymphoid cell lines MOLT-4 and Raji, but had essentially no activity against myeloid cell lines KG1A and KBM5 (Figure 2 ). In contrast, donor ␥␦ + T cells from cultures in combination with recipient primary AML and pan-␦ mAb preferentially expressed V␦2 and did not differ significantly from the phenotype of ␥␦ + T cells cultured on pan-␦ mAb alone. Respective donor-derived ␥␦ + T cells from cultures with recipient primary AML did not bind the recipient leukemia (Figure 1c ) and did not exhibit measurable cytotoxicity to it (Figure 1d ). These observations suggest that ␥␦ + T cell expansion in AML-based cultures may have derived predominantly from the immobilized antibody rather than the AML. In the allogeneic MLC, T cell-replete responder cells proliferated well against irradiated stimulator cells in all experiments as measured by 3 H-thymidine uptake (Figure 3) . However, when an equal number (5 × 10 4 ) ␥␦ + T cells from the CD4/CD8-depleted fraction were tested, ␥␦ + T cells showed minimal 3 H-thymidine uptake in response to allogeneic stimulator cells even with supplemental IL-2 (see Materials and methods). Flow cytometric immunophenotyping of duplicate wells showed expansion of the ␣␤ + T cell population in T cell-replete responder vs allogeneic stimulator cultures, but little expansion of either the residual ␣␤ + or the enriched ␥␦ + T cell population in the CD4/CD8-depleted vs allogeneic responder wells (Figure 4 ).
Discussion
The results from this study indicate that allogeneic donorderived leukemia-specific ␥␦ + T cells can be expanded against primary leukemia from a BMT recipient simply by exposing ␥␦ + T cells to the leukemia. Cytotoxicity against recipient leukemia and immortalized lymphoid cell lines can be reliably demonstrated. In contrast, ␥␦ + T cells do not proliferate well against allogeneic mismatched stimulator cells in the mixed lymphocyte reaction. These findings suggest that ␥␦ + T cells may be useful as an allogeneic immunotherapeutic cell product with only a minimal risk of GVHD.
The striking degree of toxicity of ␥␦ + T cells against ALL shown in Figure 1 is consistent with the cytotoxicity data reported by Duval et al. 8 He reported that V␦1 + T cells from a patient with B-ALL were cytotoxic against leukemic B cell lines but did not test the primary leukemia. Steinle et al 16 also showed specific activation and expansion of V␦1 + ALL lines in response to nonclassical MHC antigens MICA and MICB. However, these antigens were not expressed by the leukemia cells from the two ALL patients (1 and 3) from whom ␥␦ + T cell-based cytotoxicity was demonstrated.
Although the leukemias in this study expressed MHC class I and II, the respective donor-derived ␥␦ + T cells did not express CD4 or CD8, suggesting that cytotoxicity was not MHC-restricted. There are several candidate antigens expressed on various neoplastic cells that would support ␥␦ + T cell-based cytotoxicity outside the recognition of MHC-associated peptides. Esslin and Formby 7 showed that in vitro activated peripheral blood ␥␦ + T cells possess MHC non-restricted cytolytic activity towards selected human tumor cell lines when compared to similarly activated ␣␤ + T cells. Others have shown that heat shock proteins, [17] [18] [19] TCT.1 20 and the nonclassical human MHC antigens MICA and MICB 16 also function as ligands for ␥␦ + T cells. Cytotoxic ␥␦ + T cells have been generated against EBV-transformed B cells, 21 Burkitt lymphoma cells, 21 Daudi lymphoma cells, 22 and against autologous maturing hematopoietic cells from a patient with aplastic anemia. 23 FBS was no longer used in cultures after patient No. 5 to avoid the possibility of presenting xenogeneic antigens from FBS to CD8 + ␥␦ T cells, resulting in activation and proliferation. The change to human AB serum has not affected the proliferative response of V␦1 + Cd4 Ϫ CD8 Ϫ in response to ALL blasts, nor the binding assay performed on patients 7 and 9.
Since ␥␦ + T cells with anti-ALL cytotoxic activity do not express CD4 or CD8, their potential for initiating GVHD may be minimal. The MLC results from this study are consistent with data from others that have shown ␥␦ + T cells not to be primary effectors of epidermal damage in cutaneous GVHD. 24 Tsuji et al 25 also demonstrated that although ␥␦ + T cells do not produce GVHD on their own, host ␥␦ + T cells can be recruited into donor ␣␤ + lesions where they are activated and induced to proliferate. Viale et al 26 also noted an increase in the ratio of V␦1:V␦2 cells in patients with acute GVHD but the significance of this finding remains undetermined. In addition, increased ␥␦ + T cells have been found in one study to be associated with viral and fungal infections during the first year following TCD BMT in patients receiving either PMRD or MUD Bone Marrow Transplantation grafts. 27 In the same study, increases in ␥␦ + T cells was not found to be associated with GVHD. Finally, data from our laboratory have shown no correlation between increased ␥␦ + T cells and the development of GVHD. 9, 10 In summary, our clinical observations and preliminary data indicate that these cells may be useful in cellular immunotherapy against leukemia. We believe this to be the first report of proliferation, binding, and cytotoxicity of donor ␥␦ + T cells to recipient primary ALL. An exciting possibility based on reports in the literature and data from our laboratory is that these cells may not be effectors of GVHD. Furthermore, the potential application of this type of cellular immunotherapy may be safer and more specific than current practice. Additional laboratory studies are needed to better define the mechanism and specificity of antileukemic ␥␦ + T cell therapy and its role in disease prevention and therapy.
